AVNS is no longer listed. Its last trade on record was Jul 24, 2026. The price and figures on this page are from its last trading day and final filings, and are no longer updated.
AVNS trades 8.0% above Wall Street's consensus target of $23.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes AVNS achieves its forward estimates and maintains a stable P/E multiple of 25.0x. This scenario reflects the blended consensus of 8 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of November 8, 2026, Avanos Medical, Inc. (AVNS) has a Wall Street consensus price target of $23.00, based on estimates from 8 covering analysts.
Analyst price targets range from a low of $20.00 to a high of $26.00, representing a 26% spread in expectations. The median target of $23.00 aligns closely with the consensus average.
The current analyst consensus rating is Hold, with 1 analysts rating the stock as a Buy or Strong Buy,6 rating it Hold, and 1 rating it Sell or Strong Sell. The bearish sentiment suggests caution about the stock at current levels.
From a valuation perspective, AVNS trades at a forward P/E of 25.0x. Analysts expect EPS to grow +166.9% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 MMSIMerit Medical Systems, Inc. | $5.2B | $87.23 | $107.33 | +23.0% | Buy | 20.0x | 15 |
 NVCRNovocure Ltd | $1.5B | $13.28 | $26.00 | +95.8% | Buy | — | 15 |
 ITGRInteger Holdings Corporation | $4.3B | $126.56 | $118.25 | -6.6% | Buy | 20.8x | 16 |
 ATRCAtriCure, Inc. | $3.0B | $58.54 | $60.17 | +2.8% | Buy | 541.5x | 20 |
 NTRANatera, Inc. | $44.5B | $310.67 | $393.16 | +26.6% | Buy | — | 28 |
 ICUIICU Medical, Inc. | $4.3B | $172.11 | $192.25 | +11.7% | Buy | 19.7x | 12 |
 ANGOAngioDynamics, Inc. | $485M | $11.73 | $19.00 | +62.0% | Hold | — | 11 |
 INVAInnoviva, Inc. | $1.4B | $19.10 | $38.00 | +99.0% | Buy | 7.9x | 11 |
 MDTMedtronic plc | $130.7B | $101.80 | $97.73 | -4.0% | Buy | 17.0x | 51 |
 BSXBoston Scientific Corporation | $63.5B | $42.75 | $54.65 | +27.8% | Buy | 13.5x | 44 |
Quick answers to the most common questions about buying AVNS stock.
Wall Street's consensus price target for AVNS is $23, -8.0% from its current price of $N/A. The below-market target from 8 analysts suggests limited near-term appreciation.
AVNS has a consensus rating of "Hold" based on 8 Wall Street analysts. The rating breakdown is mixed, with 6 Hold ratings making up the largest segment. The consensus 12-month price target of $23 implies -8.0% downside from current levels.
AVNS trades at a forward P/E of 24.99x, representing a moderate valuation. With analysts targeting $23 (-8.0% implied move), the stock appears close to fair value.
The most bullish Wall Street analyst has a price target of $26 for AVNS, while the most conservative target is $20. The consensus of $23 represents the median expectation. These targets typically reflect 12-month expectations.
AVNS is moderately covered, with 8 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 1 have Buy ratings, 6 recommend Hold, and 1 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month AVNS stock forecast based on 8 Wall Street analysts shows a consensus price target of $23, with estimates ranging from $20 (bear case) to $26 (bull case). The median consensus rating is "Hold".
AVNS trades at a forward P/E ratio of 25.0x based on next-twelve-months earnings estimates. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Analysts are cautious on AVNS, with 1 Sell ratings and a price target of $23 (-8.0% from current price). The "Hold" consensus suggests careful evaluation before buying. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
AVNS analyst price targets range from $20 to $26, a 26% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $23 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.